Gunjal Garg1, Ali Yilmaz2, Praveen Kumar3, Onur Turkoglu3, David G Mutch4, Matthew A Powell4, Barry Rosen3, Ray O Bahado-Singh3, Stewart F Graham3. 1. Karmanos Cancer Institute Mclaren Flint, 4100 Beecher Road, 48532, Flint, MI, USA. 2. Department of Obstetrics and Gynecology, William Beaumont Health, Royal Oak, MI, USA. ali.yilmaz@beaumont.org. 3. Department of Obstetrics and Gynecology, William Beaumont Health, Royal Oak, MI, USA. 4. Department of Obstetrics and Gynecology, Washington University School of Medicine, 660 S. Euclid Ave. CB 8064, St. Louis, MO, USA.
Abstract
INTRODUCTION: Epithelial ovarian cancer (EOC) remains the leading cause of death from gynecologic malignancies and has an alarming global fatality rate. Besides the differences in underlying pathogenesis, distinguishing between high grade (HG) and low grade (LG) EOC is imperative for the prediction of disease progression and responsiveness to chemotherapy. OBJECTIVES: The aim of this study was to investigate, the tissue metabolome associated with HG and LG serous epithelial ovarian cancer. METHODS: A combination of one dimensional proton nuclear magnetic resonance (1D H NMR) spectroscopy and targeted mass spectrometry (MS) was employed to profile the tissue metabolome of HG, LG serous EOCs, and controls. RESULTS: Using partial least squares-discriminant analysis, we observed significant separation between all groups (p < 0.05) following cross validation. We identified which metabolites were significantly perturbed in each EOC grade as compared with controls and report the biochemical pathways which were perturbed due to the disease. Among these metabolic pathways, ascorbate and aldarate metabolism was identified, for the first time, as being significantly altered in both LG and HG serous cancers. Further, we have identified potential biomarkers of EOC and generated predictive algorithms with AUC (CI) = 0.940 and 0.929 for HG and LG, respectively. CONCLUSION: These previously unreported biochemical changes provide a framework for future metabolomic studies for the development of EOC biomarkers. Finally, pharmacologic targeting of the key metabolic pathways identified herein could lead to novel and effective treatments of EOC.
INTRODUCTION:Epithelial ovarian cancer (EOC) remains the leading cause of death from gynecologic malignancies and has an alarming global fatality rate. Besides the differences in underlying pathogenesis, distinguishing between high grade (HG) and low grade (LG) EOC is imperative for the prediction of disease progression and responsiveness to chemotherapy. OBJECTIVES: The aim of this study was to investigate, the tissue metabolome associated with HG and LG serous epithelial ovarian cancer. METHODS: A combination of one dimensional proton nuclear magnetic resonance (1D H NMR) spectroscopy and targeted mass spectrometry (MS) was employed to profile the tissue metabolome of HG, LG serous EOCs, and controls. RESULTS: Using partial least squares-discriminant analysis, we observed significant separation between all groups (p < 0.05) following cross validation. We identified which metabolites were significantly perturbed in each EOC grade as compared with controls and report the biochemical pathways which were perturbed due to the disease. Among these metabolic pathways, ascorbate and aldarate metabolism was identified, for the first time, as being significantly altered in both LG and HG serous cancers. Further, we have identified potential biomarkers of EOC and generated predictive algorithms with AUC (CI) = 0.940 and 0.929 for HG and LG, respectively. CONCLUSION: These previously unreported biochemical changes provide a framework for future metabolomic studies for the development of EOC biomarkers. Finally, pharmacologic targeting of the key metabolic pathways identified herein could lead to novel and effective treatments of EOC.
Entities:
Keywords:
1H NMR; Metabolomics; Multivariate data analysis; Serous ovarian cancer; Targeted mass spectrometry
Authors: Mark Yarchoan; Burles A Johnson; Eric R Lutz; Daniel A Laheru; Elizabeth M Jaffee Journal: Nat Rev Cancer Date: 2017-02-24 Impact factor: 60.716
Authors: Anais Malpica; Michael T Deavers; Karen Lu; Diane C Bodurka; Edward N Atkinson; David M Gershenson; Elvio G Silva Journal: Am J Surg Pathol Date: 2004-04 Impact factor: 6.394
Authors: Richard G Moore; D Scott McMeekin; Amy K Brown; Paul DiSilvestro; M Craig Miller; W Jeffrey Allard; Walter Gajewski; Robert Kurman; Robert C Bast; Steven J Skates Journal: Gynecol Oncol Date: 2008-10-12 Impact factor: 5.482
Authors: Jianguo Xia; Rupasri Mandal; Igor V Sinelnikov; David Broadhurst; David S Wishart Journal: Nucleic Acids Res Date: 2012-05-02 Impact factor: 16.971
Authors: Samyukta Sah; Sylvia R Yun; David A Gaul; Andro Botros; Eun Young Park; Olga Kim; Jaeyeon Kim; Facundo M Fernández Journal: Metabolites Date: 2022-06-09